Ironomycin

Ironomycin is a derivative of salinomycin and potent small molecule against persister cancer stem cells, that is under preclinical evaluation by SideROS for the treatment of cancer. Ironomycin was shown to induce ferroptosis in breast cancer cell lines and its mechanism of action involves the targeting of lysosomal iron.
Wikipedia contributors, "Ironomycin", Wikipedia, revision 1383529003, retrieved 20 November 2026, source, CC BY-SA 4.0.